Oncology

Back to articles

Sipuleucel-T prolongs survival, but does not delay progression in metastatic prostate cancer

KEY POINT

In a study recently published in the New England Journal of Medicine, sipuleucel-T (Provenge—Dendreon) prolonged overall survival in men with metastatic castration-resistant prostate cancer. However, the treatment did not delay progression.

SOURCES

Kantoff PW et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.

Longo DL. New therapies for castration-resistant prostate cancer [editorial]. N Engl J Med. 2010;363:479–81.

Guthrie EW, Miller M. Prostate cancer: therapeutic vaccines. US Pharm. 2007; 32:11–24.